Asymmetrex Presents New Contract Service for Adult Tissue Stem Cell Counting at CGX17

by Asymmetrex on May 16, 2017
On May 23 in Washington, D.C., stem cell medicine biotechnology start-up Asymmetrex will present its new contract service for adult tissue stem cell counting applications to company representatives attending Cell & Gene Exchange 2017. CGX17, the first partnering conference organized by the Alliance for Regenerative Medicine, will be attended by stem cell therapy, gene therapy, gene editing, and pharmaceutical companies, all who would benefit from Asymmetrex’s technology for counting adult tissue stem cells.

On Tuesday, May 23 at 10:30 AM, James Sherley, Director of Asymmetrex, will have an ideal audience for introducing the advance in stem cell medicine that his company has recently achieved in collaboration with its partner, AlphaSTAR Corporation. Tuesday will be the second day of the Alliance for Regenerative Medicine’s first partnering conference, Cell & Gene Exchange 2017. In addition to his formal talk, Sherley will meet with interested companies in one-on-one partnering sessions to introduce them to the many advantages that Asymmetrex’s AlphaSTEM Test service offers.

Asymmetrex and AlphaSTAR partnered to develop the first method for specific counting of adult tissue stem cells. The AlphaSTEM Test is the result of the integration of Asymmetrex’s expertise in the unique cell production behavior of tissue stem cells and AlphaSTAR’s cutting-edge methods in computational simulation. By a proprietary analysis of simple cell growth data from cultures containing adult tissue stem cells, the AlphaSTEM Test technology can determine, with a high degree of precision, the number and behavior of tissue stem cells in complex cell preparations from many different types of human tissues.

For stem cell therapy companies, the AlphaSTEM Test offers the ability to determine stem cell dose for the first time. Currently, the only clinical test available for estimating whether treated patients have received sufficient stem cells is the CD34 marker for blood stem cells. However, because it does not give a specific blood stem cell dose, CD34 has poor sensitivity and specificity. The weak efficacy that CD34 does provide is limited primarily to blood stem cells. The AlphaSTEM Test offers the ability to determine specific dosing for stem cells from many different tissues.

Gene therapy and gene editing companies that genetically engineer blood stem cells – called hematopoietic stem cells (HSCs) – could also benefit from the AlphaSTEM Test service. HSCs are the targets for gene treatments because they are the only blood cells that are naturally maintained in the body for the long periods required for stable genetic cures. Because human HSCs are rare cells even in the most enriched clinical preparations, their starting number and their remaining number, respectively before and after genetic engineering procedures, are important data for optimization of the engineering and ensuring that sufficient modified HSCs are available for effective treatment.

Though minor participants in the conference, Asymmetrex will also address pharmaceutical companies. Asymmetrex has established that the AlphaSTEM Test can be employed to identify stem cell-active agents. The test has been validated with known stem cell-toxic drugs and stem cell-activating compounds. The current main service focus for Pharma is stem cell-toxic drug candidates. Stem cell toxicity causes chronic organ failure, a property that generally means a failed drug. Twenty to 30 percent of all drugs fail in Phase II and Phase III clinical trials due to intolerable toxicity. About half of these failures are due to chronic organ failure, which costs the average large pharmaceutical company $100-300 million each year. Asymmetrex’s AlphaSTEM Test could identify many of these future failures much earlier, even before animal studies, giving substantial savings to pharmaceutical companies in real dollars and patient safety. The impact would be even greater for drugs that did not manifest chronic organ failure until after they were in the marketplace.

Asymmetrex launched the AlphaSTEM Test contract service in September 2016. Thus far, adoption of the new technology has been measured. Asymmetrex’s presentation at Cell & Gene Exchange 2017 is part of the company’s mounting marketing campaign to increase awareness of the new technology in relevant fields. In addition to marketing to prospective clients, the company is discussing potential distribution partnerships with established contract research and contract medical organizations. Director Sherley is optimistic that “this is a technology that will become a must have for everyone and anyone working with adult tissue stem cells. If you are investigating them, treating with them, testing drugs with them, or supplying them, how could you pass up now knowing how many they are?”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAsymmetrex Presents New Contract Service for Adult Tissue Stem Cell Counting at CGX17

Introducing First Quality Control Test for Therapeutic Tissue Stem Cells

by Asymmetrex on March 14, 2017

On March 8-9 in Boston, stem cell medicine biotechnology start-up Asymmetrex led attendees at the 6th Annual Clinical Trials Supply New England 2017 conference in discussions about the need for quality controls for the supply of tissue stem cells used for treatments in either FDA-approved clinical trials or unregulated private stem cell clinics. Though these two stem cell treatment settings are often contrasted regarding their safety and effectiveness, Asymmetrex stressed that patient care and research progress is compromised in both because of the lack of essential quality control tests for the number and quality of transplanted tissue stem cells.

At the 6th Annual Clinical Trials Supply New England 2017 conference, held in Boston from March 8-9, James Sherley, M.D., Ph.D., director of Asymmetrex, led discussions that evaluated the quality of U.S. supplies of stem cells used in clinical trials compared to private stem cell clinics. Private stem cell clinics have been criticized for not employing research standards that are necessary to establish the therapeutic effectiveness of treatments with statistical confidence. In part because of this difference in practice, they are also often accused of making unproven claims about the effectiveness of their therapies.

Sherley presented comparisons of key operational elements to argue that, given good intent in both settings, the two different settings of stem cell treatments had both distinct and shared shortcomings. He noted, however, that the most significant shortcoming, which stem cell clinical trials and private stem cell clinics share, was perennially overlooked.

Based on the number of reported stem cell clinical trials and private stem cell clinics, Sherley estimated that close to a quarter-million patients in the U.S. now receive stem cell treatments each year. Though many of these occur within FDA-approved clinical trials, their number is dwarfed nearly 10 times by the number of treatments that occur in private stem cell clinics. It shocked the audience of clinical trial suppliers to learn that there was no stem cell quality control test performed for any of these many treatments.

Even for approved stem cell medicine treatments like bone marrow transplantation and umbilical cord blood transplant, there is no stem cell-specific quality control test available. Counts of total cells are made, but these do not adequately predict stem cell number or function. Biomarkers designated for tissue stem cells are also expressed by stem cells’ more abundant non-stem cell products. So, the biomarkers lack sufficient specificity to be used to count and monitor tissue stem cell function.

Without a quality control test for tissue stem cell number, stem cell treatments in all settings proceed without knowing the dose of treating tissue stem cells. This previously unavoidable therapeutic blind spot creates an instant treatment risk. It also precludes effective analyses to optimize treatment procedures, to compare different treatments, or to relate treatment outcomes to tissue stem cell dose. Without knowing stem cell dose, the interpretation of any stem cell treatment in terms of stem cells as the responsible agents is compromised.

In this context, Sherley announced briefly to attendees that Asymmetrex’s new AlphaSTEM Test for counting adult tissue stem cells and providing data on their viability and tissue cell renewal function represented the needed first quality control test for tissue stem cell treatments, whether in clinical trials, in private stem cell clinics, or approved therapies. In particular, he indicated that both stem cell treatment patients and progress in stem cell medicine would benefit from existing clinical trial supply companies developing into future private stem cell clinic supply companies to ensure the quality of stem cell treatment preparations. Sherley said that, of course, their partnership with Asymmetrex to implement its new stem cell-specific quality control test was an all around best solution for accelerating progress in stem cell transplantation medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexIntroducing First Quality Control Test for Therapeutic Tissue Stem Cells

AlphaSTEM Test: Established to Be a Leading Interest for Regenerative Medicine

by Asymmetrex on January 10, 2017
Boston’s stem cell medicine biotechnology start-up Asymmetrex is beginning 2017 with exciting news for its recently launched contract service for counting adult tissue stem cells. The company’s webinar, produced with the international regenerative medicine social media network RegMedNet to describe Asymmetrex’s new counting technology and its applications, was 4th among the 10 most popular content features on RegMedNet for 2016.

Asymmetrex AlphaSTEM Test Adult Tissue Stem Cell Counting Technology Established to Be a Leading Interest for Regenerative Medicine in 2016

At the end of 2015, James Sherley, M.D., Ph.D., founder and director of Asymmetrex, made a decision to enlist RegMedNet as a partner in beginning the targeted introduction of the company’s new technology for counting adult tissue stem cells to stem cell research and stem cell medicine communities internationally. RegMedNet’s focus on accelerating progress in the field of regenerative medicine promised to engage a particularly relevant community of future users of the new technology.

In early 2016, the new partnership produced a series of scientific perspectives that illuminated the long-standing need for a means to count adult tissue stem cells in several varied research and medical disciplines. These included applications needed in stem cell transplantation medicine, regenerative medicine clinical trials, drug development, and general stem cell research. The unique series of perspectives, which highlighted the scientific, medical, and clinical potential precluded for more than half a century by the inability to count tissue stem cells was followed by a webinar describing Asymmetrex’s new solution to the counting problem.

It is gratifying, to say the least, that RegMedNet visitors showed such a high degree of interest in Asymmetrex’s new AlphaSTEM Test for counting adult tissue stem cells. Establishing that such an attraction exists in this particular international forum predicts that Asymmetrex’s new contract service for specific counting and monitoring of stem cells from many different human tissues, launched in September 2016, will continue to build its client base in 2017. The company will continue to partner with RegMedNet for this purpose.

Asymmetrex Director Sherley says that he is putting the RegMedNet partnership among his good decisions for the growth and development of Asymmetrex. However, he adds, “Surely, though, this is only the first indication of the tremendous awareness of what Asymmetrex has accomplished that will follow.”

About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAlphaSTEM Test: Established to Be a Leading Interest for Regenerative Medicine

Asymmetrex Director Shares Vision for Company

by Asymmetrex on November 17, 2016
On November 15, James L. Sherley, M.D., Ph.D., Director of stem cell biomedicine technology company Asymmetrex, contributed nearly simultaneously to two related Arena International Events Group forums for clinical trials development. While presenting Asymmetrex’s stem cell medicine business vision at the event group’s 1st Annual Preclinical Development Operations Conference in Boston, a new perspective written by Sherley was published online at the Arena International news site for addressing challenges in clinical trials operations.

Asymmetrex Director Shares Vision for Company and Private Stem Cell Treatment Clinics in Two Arena International Event Group Forums

“Asymmetrex is on the path to success.” James Sherley, director of Asymmetrex, confidently spoke these words when he recounted the business development progress of the company that he founded three years earlier. Sherley was speaking at the 1st Annual Preclinical Development Operations Summit, organized by Arena International Events Group, on November 15-16, in Boston.

Developing more effective collaboration and partnership between contract research organizations (CRO) and their pharmaceutical company and cell therapy company sponsors was the major focus of the Summit. However, in addition to attendance by heads of drug development and cell therapy development from well-established companies, the Summit also included executives from new pharmaceutical and CRO start-ups. Asymmetrex, having recently launched a new contract service that provides, for the first time, tissue stem cell counting for both support of drug development and stem cell therapeutics, was invited to present. Director Sherley reviewed the company’s current business strategy and its longer-term vision of leveraging the new CRO business towards future success as an adult tissue stem cell biomanufacturing company.

Fifteen minutes before Sherley began his presentation on the first day of the Summit, at 12 pm EDT, the clinical trials news site of Arena International published a new perspective from him on the importance of private stem cell treatment clinics to the future of stem cell biomedicine. The article considers that these clinics have been generally mischaracterized regarding their motivation and their research merit. Sherley emphasizes that their presently unregulated stem cell treatments are a part of the long tradition of routine medical practice also serving as a source of scientific discovery and medical innovation. The article makes recommendations for improvements in current treatment practices in private clinics that would increase the quality of care and the utility of knowledge obtained to accelerate progress in stem cell medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAsymmetrex Director Shares Vision for Company

Asymmetrex Founder’s Stem Cell Medicine Article Featured in CTA

by Asymmetrex on November 16, 2016

Advancing Stem Cell Medicine by Supplying Private Stem Cell Clinics

James Sherley, Asymmetrex, considers the potential benefits to stem cell medicine and stem cell science

Presently, in stem cell science and stem cell medicine, there exists a high degree of prejudice against private medical practices that offer stem cell treatments. When describing these private stem cell clinics, many reports written by disapproving stem cell scientists and stem cell medicine clinicians refer to the treating physicians as charlatans exploiting patients’ desperation and ignorance for money. Additionally, they’re regarded as unknowing pawns, themselves exploited by unsavory purveyors of poorly defined purported stem cell preparations. These reports warn that the supplied preparations may not only be ineffective, but they also may not contain any stem cells at all.

In contrast to this pejorative view held by well-known scientists and physicians in the field of stem cell biomedicine, many patients and patient advocate groups actively demand freedom for private stem cell clinics to operate without interference. The general sentiment being that regulatory agencies, like the US Food and Drug Administration (FDA) might restrict private clinics from exploring potentially beneficial novel stem cell treatments.

One factor responsible for this opposing view by patients is impatience with the generally slow, often protracted, and highly expensive regulatory path that new medical treatments must travel before receiving approval for general use. But there is also a fundamental distinction at play that could be seen as giving considerable credence to patients’ call for unregulated operation of private stem cell clinics. That distinction is the difference in the core principles that motivate stem cell medicine versus those that motivate stem cell science.

To read the rest of the article click here.

Clinical Trials Arena is an editorial website that provides content as an educational resource to help address the key challenges in the global clinical trial space.

Read More
AsymmetrexAsymmetrex Founder’s Stem Cell Medicine Article Featured in CTA

Asymmetrex and Zing Conferences Partner to Address Progress in Stem Cell Medicine

by Asymmetrex on October 25, 2016

Stem cell biotechnology start-up company Asymmetrex and not-for-profit scientific conference developer Zing Conferences have teamed up to provide a unique scientific forum for identifying and solving challenging problems that currently limit progress in stem cell biomedicine. Scheduled for February 18-21 in San Diego, California in the United States, the conference will feature invited presentations from prominent experts in the fields of stem cell biology and stem cell biomedicine and talks selected from abstracts for multidisciplinary research and clinical studies submitted by November 21.

Asymmetrex and Zing Conferences Partner to Address Progress in Stem Cell Medicine

At a recent pharmaceutical industry conference, the founder and director of biotech start-up Asymmetrex, James L. Sherley, asked a panel of noted investors, who were reviewing promising new pharmaceutical and biopharmaceutical companies for investment, “What are the stem cell medicine companies on your radar screen for investment?” Silence followed. The silence was a telling indicator of the state of progress in stem cell medicine.

Although there are many companies and institutions seeking to develop therapeutics based on stem cells, new effective stem cell therapies are yet to join the half century of success by hematopoietic stem cell transplantation therapy, which includes bone marrow, cord blood, and mobilized peripheral blood treatments. Instead, there is a growing mountain of failed efforts, which in many cases have occurred after significant hype.

Many important discoveries in stem cell biology have occurred in the last two decades, but, so far, they have not translated into effective new approved therapies. In more recent years, reports of stem cell treatments in private clinics have mushroomed, but the general applicability of these procedures is uncertain, at best; and possibly, they may not be reliable at all. In both cases, approved and unregulated, many basic barriers preclude faster progress in stem cell medicine. Examples of barriers include deficient biological knowledge, stem cell technical barriers, treatment logistics barriers, regulatory barriers, and financing barriers.

During nearly nine years of leading adult tissue stem cell bioengineering research as a professor at the Massachusetts Institute of Technology, Asymmetrex director Sherley’s focus was engineering solutions for difficult problems in stem cell biomedicine. Asymmetrex’s technologies that address the technical challenges of identifying, counting, and producing adult tissue stem cells reflect this bearing and expertise. Sherley believes that “success in solving tough problems in science and medicine begins with first recognizing problems and then facing the essentiality of solving them.”

In April 2015, Sherley was approached with an opportunity to share his focus on problem solving more widely with the field of stem cell medicine. Jane Hill, CEO of Zing Conferences invited him to organize a conference in the discipline of stem cell biomedicine. “Challenges, Solutions, and Progress in Stem Cell Medicine” is the product of that invitation.

Fifteen noted experts in diverse scientific, engineering, and medical disciplines relevant to stem cell medicine accepted invitations as featured speakers for the conference. Together, they will set the agenda for recognizing, facing, and discussing possible solutions for long-standing problems in stem cell biology and stem cell medicine. The preeminent hematopoietic stem cell physician scientist Peter Quesenberry, M.D. will intrigue conference goers with a keynote address emphasizing that even the paragon of stem cell transplantation medicine, bone marrow transplantation, still has unsolved problems that keep it from its full potential.

In addition to the invited presentations, many talks will be selected from submitted abstracts of attendees that detail important problems and solutions. These presentations are anticipated to resonate with the invited topics, as well as introduce new insights that may have not yet entered the broader consciousness of the field. The deadline for abstract submissions is November 21.

Unlike many scientific conference production companies that have emerged in the past twenty years, Zing Conferences recently became a not-for-profit. Proceeds from the conference organized with Asymmetrex will be used to support conference speaker travel needs, be applied to assist in increasing the demographic diversity of conference participants, and provide funds for biomedical research. In their partnership, both Asymmetrex and Zing Conferences achieve their goal of developing a unique scientific forum that will mingle investigators of diverse background and discipline towards an integration that may prove essential to achieving more rapid advances in stem cell medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

 

Read More
AsymmetrexAsymmetrex and Zing Conferences Partner to Address Progress in Stem Cell Medicine

CEOCFO Magazine Features Asymmetrex’s ‘Revolutionary New Technology’

by Asymmetrex on October 3, 2016

Asymmetrex Director James L. Sherley, M.D., Ph.D. had a one-on-one interview with the senior editor of CEOCFO Magazine about Asymmetrex and the AlphaSTEM Test. CEOCFO Magazine is a weekly publication that produces in-depth interviews with several top corporate executives.

The interview goes into detail about the science behind the AlphaSTEM Test and why counting stem cells is important and crucial to the progression of stem cell transplant therapies, drug development, and stem cell medicine.

CEOCFO: Dr. Sherley, the tagline on your Asymmetrex website is technologies for stem cell medicine. What are you working on now?  

Dr. Sherley: Our lead product that we are working on now, that has actually completed development and we are now marketing, is a new technology for counting adult tissue stem cells. Well call it the AlphaSTEM Test.

CEOCFO: Why do we need to count them? Would give us a little context?

Dr. Sherley: If you think about the way we have done drug development and drug use since the beginning of medicine, we do it by knowing the amount of the agent that we are giving to the patient. We know the dose. If you think about any medications that you currently take, you take a certain number of milligrams and that dose information is giving you the information about how many of those drug molecules you are getting…

To read the entire interview click here.

 

Read More
AsymmetrexCEOCFO Magazine Features Asymmetrex’s ‘Revolutionary New Technology’

Asymmetrex Announces New Adult Tissue Stem Cell Counting Contract Service at BioPharm America 2016

by Asymmetrex on September 27, 2016

 

Recently at BioPharm America 2016 in Boston, September 13-15, biotech start-up company Asymmetrex announced its new AlphaSTEM Test contract service for counting adult tissue stem cells. In addition to applications for pharmaceutical drug evaluations, the company highlighted applications of the new service for stem cell medicine, gene and gene-editing therapeutics, and general stem cell biomedical research.

Asymmetrex Announces a New Adult Tissue Stem Cell Counting Contract Service to Pharmaceutical and Stem Cell Medical Companies at BioPharm America 2016 in Boston

Asymmetrex, LLC is a Boston-based start-up company whose three years of existence are benchmarked by yearly attendance to BioPharm America conferences in Boston. A signature feature of BioPharm conferences is pre-arranged one-on-one meetings primarily among pharma companies, pharma investors, and pharma suppliers. In addition, there are workshops for new companies to hone their business pitch skills, to gain knowledge of reigning and emerging industry trends, and to give presentations of their business vision and progress.

For the past three years, while developing the first technology able to count adult tissue stem cells, Asymmetrex Director James L. Sherley, M.D., Ph.D. has attended BioPharm America in Boston to update the company’s progress, increase its visibility, and extend its business network. In 2014, the company’s new AlphaSTEM Test technology was largely a concept that existed only as computer models of a new computational simulation method for counting adult tissue stem cells. In 2015, Sherley shared with conference participants experimental data to validate the company’s 2014 projections. In the 2016 conference, he announced that the company is now actively recruiting clients for a new adult tissue stem cell counting contract service.

Pharmaceutical companies are a major client group targeted for the new service. By counting tissue stem cells, drug candidates that are stem cell-toxic can be identified by the new AlphaSTEM Test service. Stem cell-toxic drugs cause chronic organ failure, which accounts for an estimated half of drug failures due to safety concerns. Currently, induction of chronic organ failure is detected by animal studies and clinical trials. Deployment of the AlphaSTEM Test service would identify such ill-fated drug candidates earlier and at a greatly reduced cost. Asymmetrex estimates that widespread adoption of its new contract service could save the U.S. pharmaceutical industry $4-5 billion each year.

A second major application for the new contract service is the determination of adult tissue stem cell dose. In current stem cell treatments, whether in unregulated private clinics, or in approved therapies like bone marrow stem cell and cord blood stem cell transplantation, or in FDA-approved clinical trials, the dose of the treating stem cells is unknown. Asymmetrex Director Sherley expressed to BioPharm America 2016 participants that the lack of stem cell dose data is an unmet need that is stifling progress in stem cell science and stem cell medicine. Sherley envisioned that, “By BioPharm America 2017, rapid adoption of Asymmetrex’s new tissue stem cell counting service could begin a revolution of change not only in how stem cell medicine is performed, but also in how it is regarded.” In a recent interview with Clinical Trials Arena, Sherley discussed the essential elements of this advance in anticipation of addressing an upcoming November Summit on Preclinical Development Operations in Boston.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAsymmetrex Announces New Adult Tissue Stem Cell Counting Contract Service at BioPharm America 2016

New Volume on Human Stem Cell Toxicology Debuts Today

by Asymmetrex on August 11, 2016

Asymmetrex Director Edits Newly Released Book on Human Stem Cell Toxicology

 

Today, August 11, 2016, Royal Society of Chemistry Publishing in the UK released a new volume that is a first scholarly treatment of the emerging research and medical discipline of human stem cell toxicology. The 175 years old organization, which is the oldest chemical society in the world, enlisted Dr. James L. Sherley, the founder and director of Asymmetrex, LLC in the US, to develop and edit the new text.

Human Stem Cell Toxicology debuts today from the revered publishing house of the Royal Society of Chemistry in the United Kingdom. As a first publication of a collection of scholarly treatments of this increasingly important topic in environmental health sciences and stem cell medicine, the new book meets very well the RSC standard of advancing excellence in the chemical sciences, including related fields like biology and medicine. The new volume is an unparalleled collection of scholarly exposés, written by leading international experts, selected to highlight the essential challenges, recent progress, and future vision of the emerging field of toxicology for human tissue stem cells.

RSC contracted Asymmetrex director James L. Sherley, M.D., Ph.D. to develop and edit the new volume. Sherley, who has multidisciplinary research expertise in stem cell biology, stem cell bioengineering, environmental toxicology, and medicine, was well suited for the endeavor. He relates, “The opportunity to create and edit Human Stem Cell Toxicology allowed me to realize a research goal of establishing a more granular appreciation of stem cell biology in the context of environmental toxicology and medicine.” Sherley hopes that readers of the new volume will no longer stammer with uncertainty over the proper use of the terms “stem cell” versus “progenitor cell” versus “stem/progenitor cell.” Although the book’s chapters include significant contents of original research, their explicative introduction, background, discussion sections integrate to provide an effective textbook and reference for students and experts of the discipline, respectively.

Everyone knows fairly well that tissue stem cells are crucial for good health. But this understanding is mostly grounded by the concept that when stem cells go awry, disease and illness result. The other side of this coin of understanding is not as widely appreciated. It is that things that harm tissue stem cells will be harbingers of disease and even death. This second perspective is the province of human stem cell toxicology.

A guiding principle of Human Stem Cell Toxicology is the recognition that the same research challenges that slow progress in stem cell medicine also slow progress in developing needed stem cell toxicology applications. These long-standing unmet research challenges are difficulty producing tissue stem cells and difficulty quantifying tissue stem cells, which are essential advances needed to engineer new tests for investigating and evaluating stem cell toxicity.

The authors in Human Stem Cell Toxicology present innovative strategies for achieving new stem cell toxicity tests that can resolve the main application needs of the field. These applications include identifying hazardous toxicants and toxins in the environment, screening out toxic drug candidates during pharmaceutical drug development, and discovery of drugs for eradicating unwanted tissue stem cells like cancer stem cells.

The new volume also holds some surprises for the world of human toxicology. Although grounded in the core principles of toxicology, examples of surprises include the introduction of new concepts like “kinetoxicity;” introduction of both direct and indirect mechanisms by which toxins and toxicants disrupt normal tissue stem cell function; and the disclosure of the toxicology of a recently discovered new type of tissue stem cell that exhibits remarkable toxicity from commonly used, and even household, medicines. Perhaps, most surprising is the absence of any description of Asymmetrex’s newest technology that solves the tissue stem cell quantification problem to enable a new assay for identifying tissue stem cell-toxic drug candidates. Sherley jokes, “I’m saving that for Human Stem Cell Toxicology II!”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

BOSTON, MA (PRWEB) AUGUST 11, 2016

Read More

AsymmetrexNew Volume on Human Stem Cell Toxicology Debuts Today

Does Counting Adult Tissue Stem Cells Have a Human Impact?

by Asymmetrex on March 30, 2016

Does Counting Adult Tissue Stem Cells Have a Human Impact?

Asymmetrex’s 3-month campaign to increase awareness of the adult tissue stem cell counting problem has focused on how its AlphaSTEM technology solution could impact research and clinical practice.  Now, the final post in the series answers the question, “Does counting adult tissue stem cells have a human impact?”

Today on RegMedNet, Asymmetrex posted its final comment in a 6-expose series to increase awareness among the international regenerative medicine community of the importance of counting adult tissue stem cells for several different areas of stem cell medicine, drug development, and tissue stem cell research.  The final post emphasizes the immediate human impact of adoption of the company’s new AlphaSTEM technology.  As highlighted on the Asymmetrex website this week, one of the most significant impacts of counting adult tissue stem cells would be immediately starting to reduce the loss and anguish currently endured by families of children treated for leukemia with cord blood samples that may have insufficient blood stem cells for their survival.  Now, the simple act of counting the number of blood stem cells in these samples would make the deaths of many children with this dreaded disease avoidable; and it would free waiting families from the distress and fear that their child might be fated to die because before it was not possible to tell if a cord blood sample had sufficient stem cells. Find more information on the greater human impact of adult tissue stem cell counting on the RegMedNet site.

As its founder and current Director, Dr. Sherley leads Asymmetrex with a mission of advancing emerging adult stem cell tissue technologies to applications in clinical drug discovery and cellular medicine. Asymmetrex is the developer and holder of a rich portfolio of recently issued patents for biotechnologies for the quantification and production of human adult tissue stem cells.

 

 

 

Read More
AsymmetrexDoes Counting Adult Tissue Stem Cells Have a Human Impact?